Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6158MR)

This product GTTS-WQ6158MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6158MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10875MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3430MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ5527MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ3668MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ3349MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ3209MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ1708MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ7672MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW